

Patient: RISCADO-CERRELLI, SUSANA I

Lab No: 2021-ZY2580557



Age: 38 years Gender: F

Reference #:

Date of Birth: Nov 02 1982

Patient ID: 2021ZY2580557

HC #: 6117552411

Referring Site ID:

Patient's Phone: (647) 330-9447

Date of Service: Sep 15 2021 09:25

Ordered by: PAULAITIS DR. C.

Reported on: Sep 15 2021 19:28

Copy To:

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Telephone: (877) 849-3637

Toll Free: (877) 849-3637

Fax: (905) 795-9891

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

Hematology

#5687

WBC		5.4	4.0 - 11.0	x E9/L
RBC		4.39	4.00 - 5.10	x E12/L
Hemoglobin		134	120 - 160	g/L
Hematocrit		0.399	0.350 - 0.450	L/L
MCV		91	80 - 100	fL
MCH		30.5	27.5 - 33.0	pg
MCHC		336	305 - 360	g/L
RDW		12.0	11.5 - 14.5	%
Platelet Count		255	150 - 400	x E9/L

Differential

Neutrophils		3.0	2.0 - 7.5	x E9/L
Lymphocytes		2.0	1.0 - 3.5	x E9/L
Monocytes		0.3	0.2 - 1.0	x E9/L
Eosinophils		0.1	0.0 - 0.5	x E9/L
Basophils		0.0	0.0 - 0.2	x E9/L
Immature Granulocytes		0.0	0.0 - 0.1	x E9/L
Nucleated RBC		0		/100 WBC

Biochemical Investigation of Anemias

Vitamin B12		197	138-652	pmol/L
Ferritin		22	5-272	ug/L

General Chemistry

Glucose Fasting		4.7	3.6 - 6.0	mmol/L
Hemoglobin A1C/Total Hemoglobin		5.3	<6.0	%

Diabetes Canada 2018 Guidelines:

Screening and Diagnosis: < 5.5 % Normal

5.5% - 5.9 % At risk

6.0% - 6.4 % Prediabetes

>OR= 6.5 % Diabetes Mellitus

If HbA1c >OR= 6.5 % and asymptomatic, confirm using Fasting Glucose, HbA1c or 75g OGTT.

Monitoring: <OR= 7.0 %

Target in adults without comorbidities. Other targets may be more appropriate in children, elderly and patients with comorbidities.

Results may not accurately reflect mean blood glucose in patients with hemoglobin variants, disorders associated with abnormal erythrocyte

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.

Patient: RISCADO-CERRELLI, SUSANA I

Lab No: 2021-ZY2580557



Age: 38 years Gender: F

Reference #:

Date of Birth: Nov 02 1982

Patient ID: 2021ZY2580557

HC #: 6117552411

Referring Site ID:

Patient's Phone: (647) 330-9447

Date of Service: Sep 15 2021 09:25

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Ordered by: PAULAITIS DR. C.

Reported on: Sep 15 2021 19:28

Telephone: (877) 849-3637
Toll Free: (877) 849-3637
Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

General Chemistry

Creatinine		73	50-100	umol/L
Glomerular Filtration Rate (eGFR)		90		

turnover, severe renal and liver disorders.

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 4 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

Bilirubin Total		7	<20	umol/L
Alkaline Phosphatase		74	35-120	U/L
Alanine Aminotransferase		12	<36	U/L

Lipids

Hours After Meal		12		Hours
Triglyceride		1.83		mmol/L
Cholesterol		5.87		mmol/L
HDL Cholesterol		1.28		mmol/L

New formulation (24/Sep/2018): In some patients with abnormal liver function, the HDL-c result may be different due to the presence of lipoproteins with abnormal lipid distribution.

Non HDL Cholesterol		4.59		mmol/L
---------------------	--	------	--	--------

Non HDL-Cholesterol is not affected by the fasting status of the patient.

LDL Cholesterol		3.76		mmol/L
-----------------	--	------	--	--------

Consider the non HDL-C value as an alternate lipid target if monitoring treatment in intermediate or high risk patients.

Cholesterol/HDL Cholesterol Lipid Target Values		4.6		
--	--	-----	--	--

Lipid Target Values should be based on patient 10 year CVD risk assessment.

! High or Intermediate CVD risk

-----!
Primary ! LDL-C < or = 2.0 mmol/L OR

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.

Patient: RISCADO-CERRELLI, SUSANA I

Lab No: 2021-ZY2580557



Age: 38 years Gender: F

Reference #:

Date of Birth: Nov 02 1982

Patient ID: 2021ZY2580557

HC #: 6117552411

Referring Site ID:

Patient's Phone: (647) 330-9447

Date of Service: Sep 15 2021 09:25

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Ordered by: PAULAITIS DR. C.

Reported on: Sep 15 2021 19:28

Telephone: (877) 849-3637
Toll Free: (877) 849-3637
Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

Lipids

Tx target ! > or = 50% decrease in LDL-C

!

Alternate ! Non HDL-C < or = 2.6 mmol/L OR

Tx target ! ApoB < or = 0.8 g/L

-----!-----

! Low CVD risk

-----!-----

Primary !> or = 50% decrease in LDL-C

Tx target !

Thyroid Function

Thyroid Stimulating Hormone [TSH]

1.3

0.32-4.00

mIU/L

Thyroxine Free [Free T4]

11

9-19

pmol/L

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.